Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc.  today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE capsules, a new oral granules...

Related Keywords

San Diego ,California ,United States ,Neurocrine Biosciences ,Neurocrine Bioscience ,Eiryw Roberts ,Drug Administration ,Prnewswire Neurocrine Biosciences Inc ,Facebook ,Twitter ,Neurocrine Biosciences Inc ,Nasdaq ,Exchange Commission ,Linkedin ,Chief Medical Officer ,Tardive Dyskinesia ,Chorea Associated ,Malignant Syndrome ,Prescribing Information ,Boxed Warning ,Tardive Dyskinesia Patient ,Disease Patient ,All Rights ,Markets ,